In this section
@article{Tripp:2017:10.1128/JVI.01302-17,
author = {Tripp, RA and Power, UF and Openshaw, PJM and Kauvar, LM},
doi = {10.1128/JVI.01302-17},
journal = {Journal of Virology},
title = {Respiratory Syncytial Virus (RSV): Targeting the G Protein Provides a New Approach for an Old Problem.},
url = {http://dx.doi.org/10.1128/JVI.01302-17},
volume = {92},
year = {2017}
}
TY - JOUR
AB - Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI) annually affecting >2 million children in the US <5 years old. In the elderly (>65 years old), RSV results in ∼175,000 hospitalizations annually in the US with worldwide incidence ∼34 million. There is no approved RSV vaccine and treatments are limited. Recently, a Phase 3 trial in the elderly using a recombinant RSV F protein vaccine failed to meet its efficacy objectives, namely prevention of moderate-to-severe RSV-associated LRTI and reduced incidence of acute respiratory disease. Moreover, a recent Phase 3 trial evaluating suptavumab (REGN2222), an antibody to RSV F protein, did not meet its primary endpoint of preventing medically attended RSV infections in pre-term infants. Despite these setbacks, numerous efforts targeting the RSV F protein with vaccines, antibodies, and small molecules continue based on the commercial success of a monoclonal antibody (mAb) against the RSV F protein (palivizumab). As the understanding of RSV biology has improved, the other major coat protein, the RSV G protein, has re-emerged as an alternative target reflecting progress in understanding its roles in infecting bronchial epithelial cells and in altering the host immune response. In mouse models, a high-affinity, strain-independent human mAb to the RSV G protein has shown potent direct antiviral activity combined with the alleviation of virus-induced immune system effects that contribute to disease pathology. This mAb, being prepared for clinical trials, provides a qualitatively new approach to managing RSV for populations not eligible for prophylaxis with palivizumab.
AU - Tripp,RA
AU - Power,UF
AU - Openshaw,PJM
AU - Kauvar,LM
DO - 10.1128/JVI.01302-17
PY - 2017///
SN - 1098-5514
TI - Respiratory Syncytial Virus (RSV): Targeting the G Protein Provides a New Approach for an Old Problem.
T2 - Journal of Virology
UR - http://dx.doi.org/10.1128/JVI.01302-17
UR - http://hdl.handle.net/10044/1/56406
VL - 92
ER -
